title: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
abstract: BACKGROUND
  The role of molecular markers in predicting the response to treatment of breast cancer is poorly defined. The Cancer and Leukemia Group B (CALGB) conducted a randomized adjuvant-chemotherapy trial (CALGB 8541) comparing three doses (high, moderate, and low) of cyclophosphamide, doxorubicin, and fluorouracil in 1572 women with node-positive breast cancer. This study (CALGB 8869) was designed to determine whether the DNA index, the S-phase fraction, c-erbB-2 expression, or p53 accumulation could be used as a marker to identify a subgroup of patients more likely than others to benefit from high doses of chemotherapy.
  
  
  METHODS
  Tissue blocks were obtained from 442 patients randomly selected from the larger CALGB trial. Paraffin sections from the primary lesions were analyzed for DNA content, S-phase fraction, c-erbB-2 expression, and p53 accumulation.
  
  
  RESULTS
  Patients randomly assigned to the high-dose regimen of adjuvant chemotherapy had significantly longer disease-free and overall survival if their tumors had c-erbB-2 overexpression. No further information was gained by adding the data on S-phase fraction or p53 accumulation to the analysis. There was no clear evidence of a dose-response effect in patients with minimal or no c-erbB-2 expression.
  
  
  CONCLUSIONS
  There is a significant dose-response effect of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil in patients with overexpression of c-erbB-2 but not in patients with no c-erbB-2 expression or minimal c-erbB-2 expression. Overexpression of c-erbB-2 may be a useful marker to identify the patients who are most likely to benefit from high doses of adjuvant chemotherapy.
authors.affiliation: Bowman Gray School of Medicine, Winston-Salem, N.C.
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: A D
authors.initials: AD
authors.lastname: Thor
authors.forename: D A
authors.initials: DA
authors.lastname: Berry
authors.forename: T
authors.initials: T
authors.lastname: Kute
authors.forename: E T
authors.initials: ET
authors.lastname: Liu
authors.forename: F
authors.initials: F
authors.lastname: Koerner
authors.forename: C T
authors.initials: CT
authors.lastname: Cirrincione
authors.forename: D R
authors.initials: DR
authors.lastname: Budman
authors.forename: W C
authors.initials: WC
authors.lastname: Wood
authors.forename: M
authors.initials: M
authors.lastname: Barcos
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000032:analysis; D004317:Doxorubicin / Q000008:administration & dosage; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases; D016196:S Phase; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D004273:DNA, Neoplasm; D004317:Doxorubicin; D066246:ErbB Receptors; D005472:Fluorouracil; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases